GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mind Medicine Inc (OTCPK:MMCWF) » Definitions » Total Liabilities

Mind Medicine (Mind Medicine) Total Liabilities : $79.47 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Mind Medicine Total Liabilities?

Mind Medicine's Total Liabilities for the quarter that ended in Mar. 2024 was $79.47 Mil.

Mind Medicine's quarterly Total Liabilities increased from Sep. 2023 ($45.57 Mil) to Dec. 2023 ($46.41 Mil) and increased from Dec. 2023 ($46.41 Mil) to Mar. 2024 ($79.47 Mil).

Mind Medicine's annual Total Liabilities increased from Dec. 2021 ($12.34 Mil) to Dec. 2022 ($19.08 Mil) and increased from Dec. 2022 ($19.08 Mil) to Dec. 2023 ($46.41 Mil).


Mind Medicine Total Liabilities Historical Data

The historical data trend for Mind Medicine's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mind Medicine Total Liabilities Chart

Mind Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Total Liabilities
5.65 12.34 19.08 46.41

Mind Medicine Quarterly Data
Sep19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.19 36.11 45.57 46.41 79.47

Mind Medicine Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Mind Medicine's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=32.246+(14.129+0.031999999999995
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=46.41

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=124.541-78.134
=46.41

Mind Medicine's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=65.269+(14.19+0.014999999999999
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=79.47

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=275.533-196.059
=79.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mind Medicine Total Liabilities Related Terms

Thank you for viewing the detailed overview of Mind Medicine's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Mind Medicine (Mind Medicine) Business Description

Traded in Other Exchanges
Address
One World Trade Center, Suite 8500, New York, NY, USA, 10007
Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The firm is having an approach towards developing the next generation of psychedelic inspired medicines and therapies.